In this international , multicenter , randomized , double-blind , active-controlled , crossover , confirmatory phase III trial ( adept ( ) @ ) in patients with hemophilia A or B and inhibitors , bleeds were randomized @ : @ to treatment with vatreptacog alfa ( one to three doses at @ g kg ( -@ ) ) or rFVIIa ( one to three doses at @ g kg ( -@ ) ) .